Fig. 4From: Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatmentRole of γ-tocotrienol, gefitinib, and erlotinib in suppressing EGF receptor-dependent mitogenic signaling pathwaysBack to article page